StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Free Report) in a report released on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.
Cumberland Pharmaceuticals Price Performance
Cumberland Pharmaceuticals stock opened at $1.56 on Tuesday. Cumberland Pharmaceuticals has a 1 year low of $1.43 and a 1 year high of $2.36. The firm has a 50 day moving average price of $1.91 and a 200 day moving average price of $1.89. The company has a market cap of $22.12 million, a price-to-earnings ratio of -3.55 and a beta of 0.16. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.28.
Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last posted its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. The firm had revenue of $9.35 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%.
Institutional Investors Weigh In On Cumberland Pharmaceuticals
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Featured Stories
- Five stocks we like better than Cumberland Pharmaceuticals
- Insider Buying Explained: What Investors Need to Know
- Silicon Motion Proves That AI in Motion Stays in Motion
- Which Wall Street Analysts are the Most Accurate?
- Undervalued UnitedHealth Group Won’t Be For Long
- The 3 Best Retail Stocks to Shop for in August
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.